Editing Benzphetamine (section)

==Pharmacology==
Benzphetamine is a [[sympathomimetic]] [[amine]] and is classified as an [[anorectic]].<ref>{{cite journal | vauthors = Valentine JL, Middleton R | title = GC-MS identification of sympathomimetic amine drugs in urine: rapid methodology applicable for emergency clinical toxicology | journal = Journal of Analytical Toxicology | volume = 24 | issue = 3 | pages = 211–222 | date = April 2000 | pmid = 10774541 | doi = 10.1093/jat/24.3.211 }}</ref> The drug's main function is to reduce appetite, which in turn reduces caloric intake.<ref>{{Cite web |title=Benzphetamine (oral route) |url=https://www.mayoclinic.org/drugs-supplements/benzphetamine-oral-route/description/drg-20070952 |access-date=2025-03-22 |website=Mayo Clinic |language=en}}</ref><ref>{{Cite web |title=Benzphetamine tablets |url=https://my.clevelandclinic.org/health/drugs/19071-benzphetamine-tablets |website=Cleveland Clinic}}</ref>

Although the mechanism of action of the sympathomimetic appetite suppressants in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. [[Amphetamine]] and related sympathomimetic medications (such as benzphetamine) are thought to stimulate the release of [[norepinephrine]] and/or [[dopamine]] from storage sites in nerve terminals of the lateral hypothalamic feeding center, thereby producing a decrease in appetite. This release is mediated through the binding of benzphetamine to [[VMAT2|VMAT<sub>2</sub>]] and inhibiting its function, causing a release of these neurotransmitters into the synaptic cleft through their reuptake transporters. [[Tachyphylaxis]] and tolerance have been demonstrated with all drugs of this class.<ref>{{Citation |title=Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors |date=2012 |work=LiverTox: Clinical and Research Information on Drug-Induced Liver Injury |url=https://www.ncbi.nlm.nih.gov/books/NBK548187/ |access-date=2025-03-22 |place=Bethesda (MD) |publisher=National Institute of Diabetes and Digestive and Kidney Diseases |pmid=31643515}}</ref><ref>{{cite journal | vauthors = Bernstein AI, Stout KA, Miller GW | title = The vesicular monoamine transporter 2: an underexplored pharmacological target | journal = Neurochemistry International | volume = 73 | pages = 89–97 | date = July 2014 | pmid = 24398404 | pmc = 5028832 | doi = 10.1016/j.neuint.2013.12.003 }}</ref>

Benzphetamine has a [[metabolic half life|half-life]] of 4 to 6{{nbsp}}hours.<ref name="Woo2015">{{cite book | vauthors = Woo T |date= 2015-08-03|title= Pharmacotherapeutics for Advanced Practice Nurse Prescribers | edition = 4th |page= 226|publisher= F.A. Davis Company |isbn=978-0-8036-3827-3}}</ref>